NORD gratefully acknowledges William F. Balistreri, MD, Director, Pediatric Liver Care Center, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital, for assistance in the preparation of this report.
"Neonatal hepatitis" is a somewhat imprecise, general term traditionally used to denote injury to the liver that occurs shortly after birth; in my opinion, it is more appropriate to refer to these disorders as “Neonatal Cholestasis”. Neonatal Cholestasis may be caused by viruses, metabolic disease or genetic disorders, as well as other rare diseases that affect or impair the function of the liver.
In some children, the cause of liver injury is unknown - these cases are referred to as idiopathic neonatal hepatitis (INH). The symptoms of idiopathic neonatal hepatitis may vary greatly from one individual to another. Symptoms of liver disease often occur including yellowing of the whites of the eyes and the skin (jaundice), enlargement of the liver (hepatomegaly), unusually dark urine, and poor growth. Some individuals with idiopathic neonatal hepatitis fully recover from the condition (sporadic or transient forms); however, some will progress to chronic liver disease (persistent or progressive forms).
Regarding neonatal cholestasis: cholestasis refers to impaired flow of bile at any point from the liver cells into the intestine.
The liver is located on the right side of the abdominal cavity just under the rib cage. The liver has many different functions including filtering harmful substances (toxins) out of the bloodstream, synthesizing proteins, storing essential vitamins, helping to breakdown (metabolize) food to use as energy, creating components that help the blood form clots in response to injury, and producing bile, a liquid that plays an essential role in breaking down fats in the small intestine.
In many cases, the first sign of liver disease is yellowing of the whites of the eyes and the skin (jaundice). Some infants with idiopathic neonatal hepatitis may also have an enlarged liver (hepatomegaly). Additional signs that may occur include unusually dark urine and pale or clay-colored (acholic) stools.
The disorder can range from a mild, temporary (transient) disease that improves without treatment to more serious forms that cause additional complications. The common symptoms of liver disease may appear anytime during the first few weeks of life. By the age of 2 to 3 months, it becomes clear that an infant with neonatal hepatitis is not gaining weight and is growing at a slower than normal rate (failure to thrive). The infant may be irritable because of excessively itchy skin (pruritus). Other symptoms may include enlargement of the spleen (splenomegaly).
In more serious forms of neonatal hepatitis additional symptoms can occur including easy bruising, prolonged bleeding, infection (sepsis) and/or the accumulation of body fluids within the abdomen (ascites) in the later stages of chronic liver injury. Liver (hepatic) failure may eventually develop in some individuals with severe forms of neonatal hepatitis.
Neonatal hepatitis, specifically Neonatal Cholestasis, in general, has many different causes including several viruses including cytomegalovirus and the herpes viruses; various metabolic liver diseases or genetic disorders such as alpha-1-antitrypsin deficiency. Rare disorders may also impair the function of the liver. All of these disorders are usually diagnosed fairly promptly.
However, by definition, the cause of idiopathic neonatal hepatitis is not known. Most cases are believed to occur randomly (sporadically). Idiopathic neonatal hepatitis is responsible for 10-25 % of infants with neonatal cholestasis –in which the flow of bile from the liver is reduced or blocked, resulting in jaundice.
According to the medical literature, 15-20% of cases of idiopathic neonatal hepatitis run in families (familial form) suggesting that genetic factors play a role in its development.
The incidence of idiopathic neonatal hepatitis in the general population is unknown. The proportion of cases classified as “idiopathic” has diminished as advanced diagnostic techniques and a better molecular understanding of cholestatic diseases in general have allowed physicians to diagnose many infants as being affected with specific syndromes. In the past, these infants would have been included as having idiopathic neonatal hepatitis.
The key is early recognition of neonatal jaundice (elevated levels of conjugated bilirubin in the blood – hyperbilirubinemia) – this allows the timely initiation of a diagnostic evaluation, the goals of which are to identify treatable disorders. Therefore any infant jaundiced beyond 14 days of life should have blood test done to determine if the jaundice is due to cholestasis (elevated conjugated bilirubin levels) or is associated with elevated unconjugated bilirubin levels. The latter is normal (“physiologic jaundice”) or related to breast milk feeding
Idiopathic neonatal hepatitis is a diagnosis attained by excluding other conditions. Tests may be conducted to rule out viral as well as metabolic diseases and other genetic causes of liver disease. Blood tests may reveal decreased levels of certain vitamins because of the failure to the body to proper breakdown injected fats and fat soluble vitamins.
The structure of the liver and the surrounding ducts and blood vessels can be examined by ultrasonography. In some cases, a liver biopsy may be necessary. During a biopsy, a needle and syringe are used to remove a small piece of liver tissue. This sample is studied under a microscope. A liver biopsy may be able to rule out other liver disorders such as those that affect the inside of the liver (intrahepatic disorders) and extrahepatic disease (biliary atresia).
Careful attention to nutritional needs and diet are essential for infants with this disorder. Special supplements (i.e., fat-soluble vitamins), formulas, and/or dietary restrictions may be suggested by the physician. Special infant formulas may be prescribed, for example, malabsorption of long-chain triglycerides may be corrected with formulas that contain medium-chain triglycerides.
There is no specific treatment available for infants with idiopathic neonatal hepatitis. Treatment is directed toward the specific symptoms that are apparent in each individual.
If itching (pruritus) becomes a problem, a drug that has been used to treat itching associated with liver disease is ursodeoxycholic acid.
A surgical choice of last resort for infants who develop end-stage liver disease is a liver transplantation.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Contact for additional information about neonatal cholestasis:
William F. Balistreri, M.D.
Director, Pediatric Liver Care Center
Division of Pediatric Gastroenterology,
Hepatology and Nutrition
Cincinnati Children’s Hospital
3333 Burnet Avenue
Cincinnati, Ohio 45229-3039
Behrman RE, Kliegman RM, Jenson HB. Eds. Nelson Textbook of Pediatrics. 20th Edition. Elsevier Saunders. Philadelphia, PA; 2016.
Suchy F, Sokol R, Balistreri WF, eds. Liver Disease in Children, 4th Edition. Cambridge University Press, 2014.
Patrinos ME, Harrigan R. Idiopathic Neonatal Hepatitis. NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:288.
Balistreri WF, Bezerra JA. Whatever happened to neonatal hepatitis? Clin Liver Dis. 2006;10:27-53.
The Merck Manuals Online Medical Library. Neonatal Cholestasis. Last Update January 2015. Available at: http://www.merck.com/mmpe/sec19/ch275/ch275f.html Accessed December 5, 2016.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100